Index RUT P/E - EPS (ttm) -3.75 Insider Own 16.53% Shs Outstand 69.61M Perf Week 9.60%
Market Cap 4.24B Forward P/E - EPS next Y -4.77 Insider Trans -5.67% Shs Float 62.71M Perf Month 100.89%
Income -237.22M PEG - EPS next Q -1.16 Inst Own 90.93% Short Float 5.34% Perf Quarter 82.97%
Sales 0.00M P/S - EPS this Y -37.36% Inst Trans 3.54% Short Ratio 2.95 Perf Half Y 124.12%
Book/sh 10.61 P/B 5.32 EPS next Y -20.04% ROA -32.66% Short Interest 3.35M Perf Year 168.88%
Cash/sh 9.55 P/C 5.91 EPS next 5Y -19.08% ROE -35.90% 52W Range 15.32 - 58.40 Perf YTD 102.77%
Dividend Est. - P/FCF - EPS past 5Y 1.03% ROI -30.65% 52W High -3.41% Beta -0.22
Dividend TTM - Quick Ratio 17.25 Sales past 5Y 0.00% Gross Margin - 52W Low 268.21% ATR (14) 3.74
Dividend Ex-Date - Current Ratio 17.25 EPS Y/Y TTM -59.03% Oper. Margin - RSI (14) 83.78 Volatility 5.84% 7.08%
Employees 56 Debt/Eq 0.05 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 78.27
Option/Short Yes / Yes LT Debt/Eq 0.05 EPS Q/Q -46.82% Payout - Rel Volume 1.13 Prev Close 53.85
Sales Surprise - EPS Surprise -19.49% Sales Q/Q - Earnings Nov 08 BMO Avg Volume 1.13M Price 56.41
SMA20 60.93% SMA50 76.30% SMA200 108.28% Trades
Volume 1,280,850 Change 4.75%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-25 Upgrade BofA Securities
Neutral → Buy
$35 → $63
Jan-27-25 Reiterated H.C. Wainwright
Buy
$50 → $72
Nov-18-24 Initiated Citigroup
Buy
$65
Apr-22-24 Resumed BofA Securities
Neutral
$30
Sep-19-23 Initiated Cantor Fitzgerald
Overweight
$69
Aug-28-23 Initiated UBS
Buy
$83
Jan-27-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$40 → $65
Sep-14-22 Upgrade Evercore ISI
In-line → Outperform
$10 → $50
Oct-19-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
$27
Sep-10-21 Initiated BofA Securities
Buy
$40
Feb-26-21 Initiated Guggenheim
Buy
$54
Sep-10-20 Initiated Morgan Stanley
Overweight
$70
Jul-20-20 Reiterated H.C. Wainwright
Buy
$45 → $62
Jul-07-20 Initiated Chardan Capital Markets
Buy
$79
Jul-01-20 Reiterated H.C. Wainwright
Buy
$33 → $45
Mar-02-20 Initiated H.C. Wainwright
Buy
$33
Feb-10-20 Initiated Canaccord Genuity
Buy
$36
Jul-15-19 Initiated ROTH Capital
Buy
$34
Jul-15-19 Initiated JP Morgan
Overweight
$28
Jul-15-19 Initiated Jefferies
Buy
$28
Show Previous Ratings
Feb-03-25 07:25PM
12:28PM
Feb-02-25 06:21PM
04:35PM
Jan-30-25 04:05PM
05:39AM
Loading…
Jan-29-25 05:39AM
Jan-28-25 09:30PM
11:14AM
08:40AM
Jan-27-25 04:24PM
(Investor's Business Daily) +97.52%
04:01PM
12:13PM
11:27AM
11:10AM
10:57AM
09:01AM
Loading…
09:01AM
06:30AM
Jan-24-25 04:05PM
Jan-13-25 07:00AM
Jan-09-25 12:18PM
Jan-07-25 07:00AM
Dec-04-24 12:59PM
Nov-26-24 07:00AM
Nov-15-24 11:00AM
Nov-13-24 04:05PM
Nov-12-24 11:00PM
Nov-08-24 07:00AM
Nov-02-24 12:00PM
Nov-01-24 04:06AM
Oct-30-24 06:00AM
07:00AM
Loading…
Oct-21-24 07:00AM
Oct-17-24 03:02PM
Oct-16-24 08:44AM
Oct-15-24 06:10PM
Sep-30-24 07:00AM
Sep-12-24 01:12AM
Sep-09-24 07:00AM
Sep-05-24 12:02AM
Sep-02-24 05:22PM
Aug-28-24 04:05PM
Aug-09-24 02:53PM
07:00AM
Jul-16-24 12:00PM
Jun-28-24 10:40AM
Jun-24-24 01:04PM
Jun-21-24 11:06AM
Jun-19-24 02:45PM
Jun-17-24 10:23AM
Jun-13-24 03:57PM
09:00AM
Jun-11-24 07:00AM
Jun-10-24 10:14AM
Jun-08-24 08:15AM
Jun-06-24 10:39AM
Jun-03-24 09:57AM
May-30-24 09:16PM
May-29-24 07:00AM
May-23-24 02:12PM
May-15-24 09:26AM
May-12-24 09:01PM
May-10-24 01:54PM
07:45AM
07:00AM
May-08-24 07:00AM
Apr-30-24 08:00AM
Apr-22-24 06:00AM
Mar-20-24 01:32PM
12:58PM
Mar-18-24 07:00AM
(The Wall Street Journal)
Mar-08-24 04:02PM
Mar-07-24 04:01PM
Mar-06-24 11:54PM
Mar-05-24 09:13PM
02:12PM
Mar-04-24 04:21PM
04:04PM
(Investor's Business Daily)
12:30PM
(The Wall Street Journal)
11:59AM
09:23AM
(Investor's Business Daily)
06:22AM
06:09AM
06:00AM
04:00AM
Mar-01-24 09:55AM
Feb-29-24 08:00AM
07:00AM
Feb-06-24 10:48AM
Feb-05-24 09:55AM
Jan-30-24 09:40AM
Jan-03-24 08:15AM
Dec-18-23 07:00AM
Dec-13-23 03:06AM
Dec-05-23 01:34PM
12:36PM
Nov-14-23 07:21PM
Nov-13-23 07:00AM
Nov-10-23 08:57AM
Nov-08-23 07:00AM
Oct-17-23 04:05PM
Oct-12-23 04:38PM
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yale Catriona Chief Development Officer Jan 27 '25 Option Exercise 10.48 53,590 561,807 149,238 Jan 31 09:14 AM Yale Catriona Chief Development Officer Jan 27 '25 Sale 56.25 53,590 3,014,216 95,648 Jan 31 09:14 AM Yale Catriona Chief Development Officer Jan 27 '25 Option Exercise 21.10 49,074 1,035,461 144,722 Jan 31 09:14 AM Yale Catriona Chief Development Officer Jan 27 '25 Sale 55.72 49,074 2,734,212 95,648 Jan 31 09:14 AM Rolph Timothy Chief Scientific Officer Jan 27 '25 Option Exercise 20.51 31,250 640,942 201,487 Jan 29 08:43 PM Rolph Timothy Chief Scientific Officer Jan 27 '25 Sale 55.77 31,250 1,742,958 170,237 Jan 29 08:43 PM Lamy Patrick Senior VP, Commercial Strategy Jan 27 '25 Option Exercise 19.87 4,000 79,480 38,492 Jan 29 08:43 PM Lamy Patrick Senior VP, Commercial Strategy Jan 27 '25 Sale 57.03 5,000 285,150 33,492 Jan 29 08:43 PM Cheng Andrew President and CEO Jan 27 '25 Sale 54.90 30,000 1,646,978 716,062 Jan 29 08:43 PM Young Jonathan Chief Operating Officer Jan 24 '25 Option Exercise 6.36 43,064 274,059 261,147 Jan 27 06:08 PM Cheng Andrew President and CEO Jan 23 '25 Option Exercise 0.61 50,000 30,750 746,062 Jan 27 06:07 PM CATRIONA YALE Officer Jan 27 '25 Proposed Sale 26.18 53,591 1,403,012 Jan 27 04:24 PM CATRIONA YALE Officer Jan 27 '25 Proposed Sale 26.18 69,073 1,808,331 Jan 27 04:24 PM PATRICK D LAMY Officer Jan 27 '25 Proposed Sale 26.18 6,000 157,080 Jan 27 04:23 PM Andrew Cheng President, CEO and Director Jan 27 '25 Proposed Sale 57.03 120,000 6,843,600 Jan 27 04:19 PM Timothy Rolph Officer Jan 27 '25 Proposed Sale 57.03 68,750 3,920,813 Jan 27 04:06 PM Young Jonathan Chief Operating Officer Jan 02 '25 Sale 28.03 10,000 280,330 218,083 Jan 06 02:08 PM Jonathan Young Officer Jan 02 '25 Proposed Sale 27.82 70,000 1,947,400 Jan 02 04:29 PM Lamy Patrick Senior VP, Commercial Strategy Dec 16 '24 Sale 29.13 1,000 29,130 34,258 Dec 18 09:03 PM Yale Catriona Chief Development Officer Dec 16 '24 Option Exercise 21.10 9,074 191,461 104,722 Dec 18 09:01 PM Yale Catriona Chief Development Officer Dec 16 '24 Sale 29.11 9,074 264,117 95,648 Dec 18 09:01 PM Rolph Timothy Chief Scientific Officer Dec 17 '24 Option Exercise 19.87 3,800 75,506 182,137 Dec 18 08:52 PM Rolph Timothy Chief Scientific Officer Dec 17 '24 Sale 31.10 3,800 118,172 178,337 Dec 18 08:52 PM PATRICK D LAMY Officer Dec 16 '24 Proposed Sale 28.89 1,000 28,890 Dec 16 04:30 PM Rolph Timothy Chief Scientific Officer Dec 10 '24 Option Exercise 19.87 2,450 48,682 180,787 Dec 12 08:44 PM Rolph Timothy Chief Scientific Officer Dec 10 '24 Sale 30.91 4,818 148,934 178,337 Dec 12 08:44 PM Young Jonathan Chief Operating Officer Dec 10 '24 Sale 30.79 2,503 77,067 203,783 Dec 12 08:38 PM Lamy Patrick Senior VP, Commercial Strategy Dec 10 '24 Sale 30.79 925 28,481 17,858 Dec 12 08:29 PM Yale Catriona Chief Development Officer Dec 10 '24 Sale 30.79 2,810 86,520 71,348 Dec 12 08:28 PM White William Richard Chief Financial Officer Dec 10 '24 Sale 30.79 2,817 86,735 38,335 Dec 12 08:26 PM Cheng Andrew President and CEO Dec 10 '24 Sale 30.79 7,855 241,855 597,562 Dec 12 08:24 PM Timothy Rolph Officer Dec 10 '24 Proposed Sale 30.79 25,000 769,750 Dec 10 04:25 PM Cheng Andrew President and CEO Dec 02 '24 Option Exercise 21.10 25,000 527,500 630,417 Dec 04 07:36 PM Cheng Andrew President and CEO Dec 02 '24 Sale 32.09 25,000 802,250 605,417 Dec 04 07:36 PM Young Jonathan Chief Operating Officer Dec 02 '24 Sale 32.13 10,000 321,310 206,286 Dec 04 07:34 PM Yale Catriona Chief Development Officer Nov 15 '24 Option Exercise 21.10 9,061 191,187 83,219 Nov 19 09:57 PM Yale Catriona Chief Development Officer Nov 15 '24 Sale 27.73 9,061 251,274 74,158 Nov 19 09:57 PM Yale Catriona Chief Development Officer Nov 06 '24 Option Exercise 0.61 10,000 6,150 84,158 Nov 08 05:06 PM Yale Catriona Chief Development Officer Nov 06 '24 Sale 35.19 10,000 351,890 74,158 Nov 08 05:06 PM CATRIONA YALE Officer Nov 06 '24 Proposed Sale 32.74 10,000 327,400 Nov 06 05:01 PM Young Jonathan Chief Operating Officer Nov 01 '24 Option Exercise 21.09 40,716 858,700 267,002 Nov 05 09:04 AM Young Jonathan Chief Operating Officer Nov 01 '24 Sale 31.57 50,716 1,601,252 216,286 Nov 05 09:04 AM Cheng Andrew President and CEO Nov 01 '24 Option Exercise 21.10 108,366 2,286,523 686,697 Nov 05 09:00 AM Cheng Andrew President and CEO Nov 01 '24 Sale 31.73 108,366 3,438,312 605,417 Nov 05 09:00 AM Yale Catriona Chief Development Officer Nov 01 '24 Option Exercise 21.10 15,485 326,734 89,643 Nov 01 08:59 PM Yale Catriona Chief Development Officer Oct 30 '24 Option Exercise 21.10 4,515 95,266 78,673 Nov 01 08:59 PM Yale Catriona Chief Development Officer Nov 01 '24 Sale 32.62 15,485 505,105 74,158 Nov 01 08:59 PM Yale Catriona Chief Development Officer Oct 30 '24 Sale 32.53 4,515 146,855 74,158 Nov 01 08:59 PM CATRIONA YALE Officer Nov 01 '24 Proposed Sale 30.83 29,074 896,351 Nov 01 04:46 PM Cheng Andrew President and CEO Oct 18 '24 Option Exercise 21.10 63,539 1,340,673 668,956 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 16 '24 Option Exercise 21.10 24,992 527,331 630,409 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 17 '24 Option Exercise 21.10 3,103 65,473 608,520 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 18 '24 Sale 31.53 63,539 2,003,328 605,417 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 16 '24 Sale 31.14 24,992 778,151 605,417 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 17 '24 Sale 31.12 3,103 96,559 605,417 Oct 18 08:57 PM Young Jonathan Chief Operating Officer Oct 14 '24 Option Exercise 21.09 40,000 843,600 266,286 Oct 16 08:06 PM Young Jonathan Chief Operating Officer Oct 14 '24 Sale 30.15 40,000 1,206,080 226,286 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 15 '24 Option Exercise 0.61 14,825 9,117 90,119 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 14 '24 Option Exercise 0.61 5,000 3,075 80,294 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 15 '24 Sale 30.50 14,825 452,232 75,294 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 14 '24 Sale 30.03 6,136 184,258 74,158 Oct 16 08:06 PM Andrew Cheng President, CEO and Director Oct 16 '24 Proposed Sale 29.82 225,000 6,709,500 Oct 16 04:50 PM CATRIONA YALE Officer Oct 15 '24 Proposed Sale 30.01 32,960 989,130 Oct 15 04:38 PM CATRIONA YALE Officer Oct 14 '24 Proposed Sale 29.63 6,136 181,810 Oct 15 08:04 AM Young Jonathan Chief Operating Officer Oct 01 '24 Sale 28.18 10,000 281,770 226,286 Oct 03 08:09 PM Jonathan Young Officer Oct 01 '24 Proposed Sale 28.51 110,716 3,156,513 Oct 01 04:03 PM Yale Catriona Chief Development Officer Sep 20 '24 Option Exercise 0.61 5,500 3,382 80,794 Sep 23 06:00 PM Yale Catriona Chief Development Officer Sep 20 '24 Sale 27.65 5,500 152,086 75,294 Sep 23 06:00 PM Yale Catriona Chief Development Officer Sep 18 '24 Option Exercise 0.61 3,871 2,381 79,165 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Option Exercise 0.61 2,485 1,528 77,779 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Option Exercise 0.61 2,037 1,253 77,331 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 18 '24 Sale 27.56 3,871 106,685 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Sale 27.52 2,485 68,375 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Sale 27.55 2,037 56,115 75,294 Sep 18 09:19 PM CATRIONA YALE Officer Sep 16 '24 Proposed Sale 27.34 13,893 379,835 Sep 16 04:34 PM Young Jonathan Chief Operating Officer Sep 10 '24 Sale 26.18 568 14,870 236,286 Sep 13 05:16 PM Yale Catriona Chief Development Officer Sep 10 '24 Sale 26.18 637 16,677 75,294 Sep 13 05:14 PM White William Richard Chief Financial Officer Sep 10 '24 Sale 26.18 639 16,729 41,152 Sep 13 05:13 PM Rolph Timothy Chief Scientific Officer Sep 10 '24 Sale 26.18 537 14,059 180,705 Sep 13 05:11 PM Cheng Andrew President and CEO Sep 10 '24 Sale 26.18 1,738 45,501 605,417 Sep 13 05:10 PM Young Jonathan Chief Operating Officer Sep 03 '24 Sale 26.72 5,000 133,588 236,854 Sep 05 04:08 PM Yale Catriona Chief Development Officer Sep 03 '24 Option Exercise 0.61 949 584 76,880 Sep 05 04:05 PM Yale Catriona Chief Development Officer Sep 03 '24 Sale 27.61 949 26,206 75,931 Sep 05 04:05 PM White William Richard Chief Financial Officer Aug 26 '24 Option Exercise 14.57 75,159 1,095,329 74,462 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Option Exercise 21.09 23,175 488,761 64,966 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 26 '24 Sale 27.21 75,159 2,045,152 41,791 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Sale 26.41 23,175 612,098 41,791 Aug 29 04:30 PM Yale Catriona Chief Development Officer Aug 23 '24 Option Exercise 0.61 8,851 5,443 84,782 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Option Exercise 0.61 5,200 3,198 81,131 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 23 '24 Sale 27.53 8,851 243,641 75,931 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Sale 27.51 5,200 143,073 75,931 Aug 28 11:11 AM White William Richard Officer Aug 26 '24 Proposed Sale 27.46 98,334 2,700,252 Aug 26 04:32 PM CATRIONA YALE Officer Aug 23 '24 Proposed Sale 26.11 15,000 391,650 Aug 23 04:27 PM Cheng Andrew President and CEO Aug 16 '24 Option Exercise 0.61 24,538 15,091 607,155 Aug 20 11:45 AM Young Jonathan Chief Operating Officer Aug 01 '24 Sale 26.75 5,000 133,756 241,854 Aug 02 09:32 PM White William Richard Chief Financial Officer Jul 24 '24 Option Exercise 7.01 139,083 974,833 180,874 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 25 '24 Option Exercise 7.01 22,272 156,104 64,063 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 23 '24 Option Exercise 7.01 500 3,504 42,291 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 24 '24 Sale 26.98 139,083 3,753,041 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 25 '24 Sale 27.61 22,272 614,820 41,791 Jul 25 05:54 PM
Index RUT P/E - EPS (ttm) -3.97 Insider Own 47.43% Shs Outstand 29.75M Perf Week -0.79%
Market Cap 1.86B Forward P/E - EPS next Y -5.21 Insider Trans -0.60% Shs Float 18.03M Perf Month -13.02%
Income -103.48M PEG - EPS next Q -1.11 Inst Own 50.67% Short Float 11.34% Perf Quarter 21.20%
Sales 0.00M P/S - EPS this Y -20.77% Inst Trans -1.21% Short Ratio 5.41 Perf Half Y 26.80%
Book/sh 15.73 P/B 3.45 EPS next Y -26.22% ROA -23.74% Short Interest 2.04M Perf Year -19.74%
Cash/sh 14.21 P/C 3.82 EPS next 5Y -16.08% ROE -25.03% 52W Range 25.60 - 77.60 Perf YTD -14.32%
Dividend Est. - P/FCF - EPS past 5Y - ROI -22.03% 52W High -30.00% Beta 0.73
Dividend TTM - Quick Ratio 19.36 Sales past 5Y 0.00% Gross Margin - 52W Low 112.19% ATR (14) 2.81
Dividend Ex-Date - Current Ratio 19.36 EPS Y/Y TTM -6.02% Oper. Margin - RSI (14) 35.98 Volatility 3.64% 4.82%
Employees 74 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 94.82
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -52.98% Payout - Rel Volume 0.60 Prev Close 54.99
Sales Surprise - EPS Surprise 14.17% Sales Q/Q - Earnings Nov 12 BMO Avg Volume 377.91K Price 54.32
SMA20 -6.49% SMA50 -12.04% SMA200 11.67% Trades
Volume 225,512 Change -1.22%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-05-24 Upgrade Morgan Stanley
Equal-Weight → Overweight
$85
Nov-04-24 Upgrade Raymond James
Outperform → Strong Buy
$66 → $110
Oct-23-24 Initiated Jefferies
Buy
$89
Oct-16-24 Initiated Scotiabank
Sector Outperform
Aug-22-24 Initiated Wells Fargo
Overweight
$75
Apr-01-24 Downgrade Raymond James
Strong Buy → Outperform
$40
Dec-19-23 Downgrade Morgan Stanley
Overweight → Equal-Weight
$56 → $65
Jun-09-23 Upgrade Raymond James
Outperform → Strong Buy
$50 → $75
Jun-07-23 Initiated H.C. Wainwright
Buy
$55
May-17-23 Initiated Raymond James
Outperform
$50
Apr-28-23 Initiated Cantor Fitzgerald
Overweight
$45
Apr-21-23 Initiated Stifel
Buy
$37
Apr-20-23 Initiated Morgan Stanley
Overweight
$37
Mar-23-23 Initiated BMO Capital Markets
Outperform
$40
Feb-28-23 Initiated SVB Securities
Outperform
$36
Show Previous Ratings
Jan-23-25 08:28AM
(Pharmaceutical Technology)
Jan-22-25 09:35PM
Jan-21-25 04:01PM
07:45AM
Jan-20-25 07:00PM
04:00PM
Loading…
Jan-17-25 04:00PM
Jan-10-25 09:00AM
Dec-09-24 12:00PM
Dec-08-24 08:00PM
Nov-24-24 06:10AM
Nov-13-24 08:30AM
Nov-12-24 08:00AM
Nov-11-24 10:38AM
Nov-08-24 08:30AM
Nov-05-24 09:00AM
01:44PM
Loading…
Nov-04-24 01:44PM
(Pharmaceutical Technology) +23.59%
07:50AM
Nov-01-24 04:01PM
Oct-25-24 01:00PM
Oct-23-24 08:00AM
Oct-11-24 08:00AM
Sep-19-24 08:30AM
08:30AM
Aug-30-24 08:00AM
Aug-08-24 08:00AM
Jun-28-24 08:11PM
Jun-14-24 08:03AM
07:30AM
May-30-24 09:00AM
May-14-24 10:30AM
08:00AM
Loading…
May-13-24 08:00AM
May-11-24 05:31AM
May-09-24 01:54PM
08:00AM
Apr-02-24 02:24PM
Apr-01-24 04:19PM
(Investor's Business Daily) -45.05%
08:00AM
Mar-23-24 05:31AM
Mar-21-24 08:00AM
Mar-06-24 04:30PM
Feb-26-24 08:30AM
Feb-20-24 08:30AM
Feb-09-24 09:00AM
Feb-07-24 08:00AM
Jan-03-24 05:00PM
Dec-22-23 06:35PM
Dec-20-23 04:30PM
Dec-15-23 03:01PM
Dec-11-23 08:30PM
12:00PM
Dec-08-23 07:06AM
Nov-14-23 04:44PM
Nov-13-23 09:55AM
Nov-09-23 09:34AM
08:30AM
Nov-08-23 04:30PM
Nov-02-23 09:00AM
Oct-23-23 09:15AM
Oct-03-23 08:30AM
Sep-20-23 04:30PM
Aug-30-23 04:15PM
Aug-24-23 11:20AM
(Investor's Business Daily)
Aug-11-23 08:50AM
08:00AM
Jul-27-23 09:00AM
Jul-25-23 09:55AM
Jun-22-23 04:15PM
Jun-20-23 07:33PM
Jun-13-23 10:39PM
Jun-12-23 04:00PM
01:59AM
Jun-09-23 04:13PM
(Investor's Business Daily) +15.76%
07:00AM
Jun-01-23 03:10PM
May-31-23 04:00PM
May-15-23 07:00AM
May-11-23 10:15AM
May-10-23 10:23AM
May-05-23 08:50AM
May-04-23 12:00PM
Apr-28-23 05:00AM
Apr-27-23 08:05AM
Apr-21-23 08:30AM
Apr-19-23 08:50AM
Apr-13-23 11:00AM
Mar-31-23 07:00AM
Mar-30-23 07:05AM
Mar-21-23 07:00AM
Feb-16-23 08:00AM
Feb-14-23 06:30AM
Feb-08-23 04:00PM
Jan-20-23 07:00AM
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Khara Rahul Chief Legal Officer Feb 03 '25 Option Exercise 14.69 7,500 110,175 21,535 Feb 04 05:18 PM Khara Rahul Chief Legal Officer Feb 03 '25 Sale 55.54 7,500 416,574 14,035 Feb 04 05:18 PM Atlas Venture Fund X, L.P. Shareholder Feb 04 '25 Proposed Sale 54.99 6,350 349,186 Feb 04 05:14 PM Atlas Venture Fund X, L.P. Shareholder Feb 03 '25 Proposed Sale 55.80 6,439 359,296 Feb 03 04:28 PM Khara Rahul Chief Legal Officer Jan 02 '25 Option Exercise 14.69 7,500 110,175 21,535 Jan 06 05:56 PM Khara Rahul Chief Legal Officer Jan 02 '25 Sale 62.75 7,500 470,658 14,035 Jan 06 05:56 PM Quisel John D Chief Executive Officer Dec 30 '24 Option Exercise 9.86 13,012 128,298 85,077 Jan 02 07:13 PM Quisel John D Chief Executive Officer Dec 31 '24 Option Exercise 1.01 10,000 10,100 82,065 Jan 02 07:13 PM Quisel John D Chief Executive Officer Dec 30 '24 Sale 61.95 13,012 806,058 72,065 Jan 02 07:13 PM RAHUL KHARA Officer Jan 02 '25 Proposed Sale 63.40 15,000 951,000 Jan 02 04:20 PM JOHN QUISEL Director Dec 30 '24 Proposed Sale 64.12 13,012 834,329 Dec 30 04:11 PM Quisel John D Chief Executive Officer Dec 23 '24 Option Exercise 2.65 19,820 52,523 91,885 Dec 26 05:18 PM Quisel John D Chief Executive Officer Dec 23 '24 Sale 63.14 19,820 1,251,357 72,065 Dec 26 05:18 PM JOHN QUISEL Director Dec 23 '24 Proposed Sale 64.50 19,820 1,278,390 Dec 23 04:21 PM Quisel John D Chief Executive Officer Dec 16 '24 Option Exercise 1.01 12,791 12,919 84,856 Dec 18 07:41 PM Quisel John D Chief Executive Officer Dec 16 '24 Sale 66.01 12,791 844,314 72,065 Dec 18 07:41 PM JOHN QUISEL Director Dec 16 '24 Proposed Sale 64.89 12,791 830,008 Dec 16 04:39 PM White William Richard Director Dec 02 '24 Option Exercise 3.39 1,957 6,635 1,957 Dec 04 07:43 PM White William Richard Director Dec 02 '24 Sale 64.63 1,957 126,490 0 Dec 04 07:43 PM Savage William Jacob Chief Medical Officer Nov 25 '24 Option Exercise 12.15 14,183 172,313 54,588 Nov 26 08:03 PM Savage William Jacob Chief Medical Officer Nov 25 '24 Sale 65.45 14,183 928,326 40,405 Nov 26 08:03 PM WILLIAM SAVAGE Officer Nov 25 '24 Proposed Sale 64.96 14,183 921,328 Nov 25 04:46 PM Savage William Jacob Chief Medical Officer Nov 15 '24 Option Exercise 9.86 9,158 90,298 49,563 Nov 19 06:46 PM Savage William Jacob Chief Medical Officer Nov 15 '24 Sale 59.64 9,158 546,153 40,405 Nov 19 06:46 PM WILLIAM SAVAGE Officer Nov 15 '24 Proposed Sale 60.67 9,158 555,616 Nov 15 04:39 PM White William Richard Director Nov 04 '24 Option Exercise 45.69 7,136 326,044 7,136 Nov 05 07:16 PM White William Richard Director Nov 01 '24 Option Exercise 9.86 201 1,982 201 Nov 05 07:16 PM White William Richard Director Nov 04 '24 Sale 58.61 7,136 418,206 0 Nov 05 07:16 PM White William Richard Director Nov 01 '24 Sale 46.37 201 9,319 0 Nov 05 07:16 PM White William Richard Director Nov 04 '24 Proposed Sale 47.13 7,136 336,320 Nov 04 04:07 PM White William Richard Director Nov 01 '24 Proposed Sale 44.82 2,158 96,722 Nov 01 04:19 PM White William Richard Director Oct 01 '24 Option Exercise 9.86 201 1,982 201 Oct 03 04:29 PM White William Richard Director Oct 01 '24 Sale 51.31 201 10,312 0 Oct 03 04:29 PM Savage William Jacob Chief Medical Officer Sep 16 '24 Sale 47.41 1,500 71,115 40,405 Sep 18 04:05 PM WILLIAM SAVAGE Officer Sep 16 '24 Proposed Sale 47.79 1,500 71,685 Sep 16 04:39 PM White William Richard Director Sep 03 '24 Option Exercise 3.39 1,957 6,635 1,957 Sep 05 04:06 PM White William Richard Director Sep 03 '24 Sale 49.65 1,957 97,158 0 Sep 05 04:06 PM Savage William Jacob Chief Medical Officer Sep 03 '24 Sale 50.59 1,500 75,885 41,905 Sep 04 04:05 PM WILLIAM SAVAGE Officer Sep 03 '24 Proposed Sale 50.82 1,500 76,230 Sep 03 04:15 PM White William Richard Director Aug 01 '24 Option Exercise 9.86 201 1,982 201 Aug 05 04:15 PM White William Richard Director Aug 01 '24 Sale 43.44 201 8,731 0 Aug 05 04:15 PM White William Richard Director Aug 01 '24 Proposed Sale 43.16 9,696 418,479 Aug 01 05:10 PM Quisel John D Chief Executive Officer Jul 08 '24 Option Exercise 1.01 3,000 3,030 72,065 Jul 10 04:15 PM White William Richard Director Jul 01 '24 Option Exercise 9.86 201 1,982 201 Jul 03 04:15 PM White William Richard Director Jul 01 '24 Sale 46.04 201 9,253 0 Jul 03 04:15 PM Bitterman Kevin Director Jun 17 '24 Buy 36.00 222,223 8,000,028 420,549 Jun 20 08:00 PM Ashiya Mona Director Jun 17 '24 Buy 36.00 83,334 3,000,024 941,569 Jun 20 05:27 PM ORBIMED ADVISORS LLC Director Jun 17 '24 Buy 36.00 83,334 3,000,024 941,569 Jun 20 05:19 PM White William Richard Director Jun 03 '24 Option Exercise 3.39 1,957 6,635 1,957 Jun 05 04:05 PM White William Richard Director Jun 03 '24 Sale 36.08 1,957 70,608 0 Jun 05 04:05 PM White William Richard Director May 01 '24 Option Exercise 9.86 201 1,982 201 May 03 04:05 PM White William Richard Director May 01 '24 Sale 28.63 201 5,755 0 May 03 04:05 PM White William Richard Director Apr 11 '24 Option Exercise 4.91 2,560 12,581 2,560 Apr 15 06:27 PM White William Richard Director Apr 11 '24 Sale 31.80 2,560 81,407 0 Apr 15 06:27 PM Savage William Jacob Chief Medical Officer Apr 10 '24 Option Exercise 2.65 21,870 57,956 43,405 Apr 11 05:02 PM Bitterman Kevin Director Mar 05 '24 Sale 73.50 26,157 1,922,540 677,503 Mar 07 04:40 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
